Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia

Biological Psychiatry

Volumn 47, Issue 1, 2000, Pages 8-21

  Fenton, Wayne S ^a   Hibbeln, Joseph ^b   Knable, Michael ^c  

^a Stanley Treatm Prog at Chestnut L   (United States)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^c Stanley Medical Research Institute   (United States)

Author keywords

Essential fatty acids; Membrane physiology; Phospholipids; Psychopharmacology; Schizophrenia; Treatment

Indexed keywords

CHOLESTEROL; ESSENTIAL FATTY ACID; FISH OIL; GLYCEROPHOSPHOLIPID; ICOSANOID; ION CHANNEL; MEMBRANE PHOSPHOLIPID; MONOUNSATURATED FATTY ACID; NEUROLEPTIC AGENT; NICOTINIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PHOSPHOLIPASE A2; PHOSPHOLIPASE C; PRIMROSE OIL; PROSTAGLANDIN; PROSTAGLANDIN E1; SATURATED FATTY ACID; THROMBOXANE;

DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; FATTY ACID METABOLISM; HUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SECOND MESSENGER;

BIOLOGICAL MARKERS; BRAIN; FATTY ACIDS, ESSENTIAL; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; FATTY ACIDS, UNSATURATED; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MEMBRANE LIPIDS; PHOSPHOLIPIDS; PROSTAGLANDINS; SCHIZOPHRENIA;

EID: 0034653210     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(99)00092-X     Document Type: Review

References (119)

1. 1 formation in blood platelets from patients with depression, mania and schizophrenia. Br J Psychiatry. 127:1975;591-595.
2. 2 activity in serum of neuroleptic-naive psychiatric inpatients. Psychopharmacology. 26:1993;4-9.
3. Anderson G.J., Connor W.E., Corliss J.D. Docosahexaenoic acid is the preferred dietary n-3 fatty acid for the development of the brain and retina. Pediatr Res. 27:1990;89-97.
4. Banks W., Kastin A., Rapoport S. Permeability of the blood-brain barrier to circulating free fatty acids. Yehuda S., Mostofsky D., Handbook of Essential Fatty Acid Biology; Biochemistry, Physiology, and Behavioral Neurobiology. 1997;3-14 Humana Press, Inc, New Jersey.
5. Bates C., Horrobin D.F., Ells K. Fatty acids in plasma phospholipids and cholesterol esters from identical twins concordant and discordant for schizophrenia. Schizophr Res. 6:1991;1-7.
6. Christensen O., Christensen E. Fat consumption and schizophrenia. Acta Psychiatr Scand. 78:1988;587-591.
7. Conley R.R., Buchanan R.W. Evaluation of treatment resistant schizophrenia. Schizophr Bull. 23:1997;663-674.
8. Connor W.E., Neuringer M., Lin D.S. Dietary effects on brian fatty acid composition the reversibility of n-3 fatty acid deficiency and turnover of docosahexaenoic acid in the brain, erythrocytes, and plasma of rhesus monkeys . J Lipid Research. 31:1990;237-247.
9. Davis G.C., Buchsbaum M.S., van Kammen D.P., Bunny W.E. Analgesia to pain stimuli in schizophrenia and its reversal by naltrexone. Psychiatry Res. 1:1979;61-69.
10. 31Phosphorus magnetic resonance spectroscopy of the frontal and parietal lobes in chronic schizophrenia. Biol Psychiatry. 36:1994;503-510.
11. Deicken R.F., Merrin E.L., Floyd T.C., Weiner M.W. Correlation between left frontal phospholipids and Wisconsin Card Sort Test performance in schizophrenia. Schizophr Res. 14:1995;177-181.
12. Delion S., Chalon S., Guilloteau D., Besnard J.C., Durand G. Alpha-linolenic acid deficiency alters age-related changes of dopaminergic and serotonergic neurotransmission in the rat frontal cortex. J Neurochem. 66:1996;1582-1591.
13. Delion S., Chalon S., Herault J., Guilloteau D., Besnard J.C., Durand G. Chronic dietary alpha-linolenic acid deficiency alters dopaminergic and serotonergic neurotransmission in rats. J Nutr. 124:1994;2466-2475.
14. Department of Health and Human Services, Food and Drug Administration (1997):Substances Affirmed as Generally Recognized as Safe: Menhaden Oil. Federal Register June 5, 1997; 62:30751-30757.
15. 2 and schizophrenia. Schizophr Res. 31:1998;185-196.
16. Drug Therapy Bulletin (1996):Increasing Fish Oil Intake-Any Net Benefits?34:8.
17. Feldberg W. Possible association of schizophrenia with a disturbance in prostaglandin metabolism a physiological hypothesis . Psychiatr Med. 6:1976;359-369.
18. Fiedler F., Wolkin A., Rotrosen J. Niacin-induced flush as a measure of prostaglandin activity in alcoholics and schizophrenics. Biol Psychiatr. 21:1986;1347-1350.
19. Fischer S., Werner K., Kub H.-J. Schizophrenic patients treated with high dose phenothiazine or thioxanthene become deficient in polyunsaturated fatty acids in their thrombocytes. Biochem Pharmacol. 44:1992;317-323.
20. Fong T.M., McNamee M.G. Correlation between acetylcholine receptor function and structural properties of membranes. Biochem J. 25:1986;830-840.
21. 2 and the hypofrontality hypothesis of schizophrenia. Prostaglandins Leukotrienes Essent Fatty Acids. 55:1996;109-113.
22. Gattaz W.F., Hubner CvK, Navalainen T.J. Increased serum phospholipase A activity in schizophrenia a replication study . Biol Psychiatr. 28:1990;495-501.
23. Gattaz W.F., Kollisch M., Thuren T., Virtanen J.A., Kunnunen P.K.J. Increased plasma phospholipase-A activity in schizophrenic patients reduction after neuroleptic therapy . Biol Psychiatr. 22:1987;421-426.
24. 2 activity in schizophrenia. Schizophr Res. 16:1995;1-6.
25. Gerner R., Merrill J. Cerebrospinal fluid prostaglandin E in depression, mania, and schizophrenia compared to normals. Biol Psychiatr. 18:1983;565-569.
26. Glen A.I.M., Cooper S.J., Rybaskowski J., Vadaddi K., Brayshaw N., Horrobin D.F. Membrane fatty acids, niacin flushing and clinical parameters. Prostaglandins Leukotrienes Essent Fatty Acids. 55:1996;9-15.
27. Glen A.I.M., Glen E.M.T., Horrobin D.F., Vaddadi K.S., Spellman M., Morse-Fisher N., et al. A red blood cell membrane abnormality in a subgroup of schizophrenic patients evidence for two diseases . Schizophr Res. 12:1994;53-61.
28. Graber R., Sumida C., Nunez E.A. Fatty acids and cell signal transduction. J Lipid Mediat. 9:1994;91-116.
29. Grove W.M., Andreasen N.C. Simultaneous tests of many hypotheses in exploratory research. J Nerv Ment Dis. 170:1982;3-8.
30. Hibbeln J.R., Salem N. Dietary polyunsaturated fatty acids and depression when cholesterol does not satisfy . Am J Clin Nutr. 62:1995;1-9.
31. Hoffman R.E., McGlashan T.H. Synaptic elimination, neurodevelopment and the mechanism of hallucinated "voices" in schizophrenia. Am J Psychiatry. 154:1997;1683-1690.
32. Holman C.P., Bell A.F.J. A trial of evening primrose oil in the treatment of chronic schizophrenia. J Orthomol Psychiatry. 12:1983;302-304.
33. Horrobin D.F. Schizophrenia as a prostaglandin deficiency disease. Lancet. I:1977;936-937.
34. Horrobin D.F. Schizophrenia a biochemical disorder . Biomedicine. 32:1980;54-55.
35. Horrobin D.F. The relationship between schizophrenia and essential fatty acid and eicosanoid metabolism. Prostaglandins Leukotriene Essent Fatty Acids. 46:1992;71-77.
36. Horrobin D.F. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res. 30:1998;193-208.
37. Horrobin D.F., Ally A.I., Karmali R.A., Karmazyn M., Manku M.S., Morgan R.O. Prostaglandins and schizophrenia further discussion of the evidence . Psychol Med. 8:1978;43-48.
38. Horrobin D.F., Glen A.I.M., Cantrill R.C. Clozapine elevation of membrane unsaturated lipid levels as a new mechanism of action . Schizophr Res. 24:1997;214.
39. Horrobin D.F., Manku M.S., Hillman H., Iain A., Glen A.I.M. Fatty acid levels in the brains of schizophrenics and normal controls. Biol Psychiatry. 30:1991;795-805.
40. Horrobin D.F., Manku M.S., Morse-Fisher N., Vaddadi K.S., Courtney P., Glen A.I.M., et al. Essential fatty acids in plasma phospholipids in schizophrenia. Biol Psychiatry. 25:1989;562-568.
41. 2 associated with schizophrenia. Schizophr Res. 21:1996;111-116.
42. Hudson C.J., Lin A., Cogan S., Cashman F., Warsh J.J. The niacin challenge test clinical manifestation of altered transmembrane signal transduction in schizophrenia? Biol Res. 41:1997;507-513.
43. Hudson C.J., Lin A., Horrobin D.F. Phospholipases in search of a genetic base of schizophrenia . Prostaglandins Leukotriene Essent Fatty Acids. 55:1996;119-122.
44. Hudson C.J., Young T., Li P.P., Warsh J.J. CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia. Synapse. 13:1993;278-293.
45. 1 treatment of schizophrenia. Biol Psychiatry. 19:1984;457-463.
46. Kaiya H., Horrobin D.F., Manku M.S., Morse-Fisher N. Essential and other fatty acids in plasma from schizophrenics and normal individuals from Japan. Biol Psychiatry. 30:1991;357-362.
47. 1 treatment of schizophrenia a second trial . Burrows G.D., Norma T.R., Clinical and Pharmacological Studies in Psychiatric Disorders. 1985;202-210 John Libbey, London.
48. 2 levels in schizophrenia. J Neural Transm. 77:1989;39-46.
49. Katan M.B., Deslypere J.P., van Birgelen A.P., Penders M., Zegwaard M. Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes, and adipose tissue an 18-month controlled study . J Lipid Res. 38:1997;2012-2022.
50. Kelkar H., Wakade C.G., Reddy R., Schnur D., Mukherjee S., Mahadik S.P. Altered membrane phospholipids in fibroblasts from schizophrenic patients. Biol Psychiatry. 33:1993;99A.
51. Keshavan M.S., Mallinger A.G., Pettegrew J.W., Dippold C. Erythrocyte membrane phospholipids in psychotic patients. Psychiatry Res. 49:1993;89-95.
52. Kim H.Y., Karanian J.W., Salem N. Jr. Formation of 15-lipoxygenase product from docosahexaenoic acid (22:6w3) by human platelets. Prostaglandins. 40:1990;539-549.
53. Lehman A.F. Vocational rehabilitation in schizophrenia. Schizophr Bull. 21:1995;645-656.
54. Lin A., Hudson C.J. The niacin challenge test in schizophrenia past, present and future . Prostaglandins Leukotriene Essent Fatty Acids. 55:1996;17-19.
55. Linnoila M., Whorton R., Rubinow D.R., Cowdry R.W., Ninan P.T., Waters R.N. CSF prostaglandin levels in depressed and schizophrenic patients. Arch Gen Psychiatry. 40:1983;405-406.
56. Lipper S., Werman D.S. Schizophrenia and intercurrent physical illness a critical review of the literature . Compr Psychiatry. 18:1997;11-22.
57. Lundbaek J.A., Anderson O.S. Lysophospholipids modulate channel function by altering the mechanical properties of lipid bilayers. J Gen Physiol. 104:1994;645-673.
58. Maes M., Smith R.S. Fatty acids, cytokines and major depression (editorial). Biol Psychiatry. 43:1998;313-314.
59. Mahadik S.P., Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia a review . Schizophr Res. 19:1996;1-17.
60. Mahadik S.P., Mukherjee S., Correnti E.E., Kelkar H.S., Wakade C.G., Costa R.M., et al. Plasma membrane phospholipid and cholesterol distribution in skin fibroblasts from drug-naive patients at the onset of psychosis. Schizophr Res. 13:1994;239-247.
61. Mahadik S.P., Mukherjee S., Horrobin D.F., Jenkins K., Correnti E.E., Scheffer R.E. Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients comparison with bipolar patients and normal subjects . Psychiatry Res. 63:1996;133-142.
62. Mahadik S.P., Shendarkar N.S., Scheffer R.E., Mukherjee S., Correnti E.E. Utilization of precursor essential fatty acids in culture by skin fibroblasts from schizophrenic patients and normal controls. Prostaglandins Leukotriene Essen Fatty Acids. 55:1996;65-70.
63. Malnoe A., Milon H., Reme C. Effect of in vivo modulation of membrane docosahexaenoic acid levels on the dopamine-dependent adenylate cyclase activity in the rat retina. J Neurochem. 55:1990;1480-1485.
64. Marchand W.E., Sarota B., Marble H.C., Leavy T.M., Burbank C.B., Bellinger M.J. Occurrence of painless acute surgical disorders in psychotic patients. New Eng J Med. 260:1969;580.
65. Martinez M., Vasquez E. MRI evidence that docosahexaenoic acid ethyl ester improves myelination in generalized peroxisomal disorders. Neurology. 51:1998;26-32.
66. Mathe A.A., Sedvall G., Wiesel F.A., Nyback H. Increased content of immunoreactive prostaglandin E in cerebrospinal fluid of patients with schizophrenia. Lancet. 1:1980;16-18.
67. Mathews C.K., van Hold K.E. Biochemistry. 2nd Ed. 1996;Benjamin Cummins & Co, New York.
68. McCreadie R.G. The Nithsdale schizophrenia surveys 16. Breast feeding and schizophrenia preliminary results and hypotheses . Br J Psychiatry. 170:1997;334-337.
69. Mellor J.E., Laugharne J.D.E., Peet M. Schizophrenic symptoms and dietary intake of n-3 fatty acids (letter to the editor). Schizophr Res. 18:1995;85-86.
70. Mellsop C., Koadlow L., Syme J., Whittingham S. Absence of rheumatoid arthritis in schizophrenia. Aust New Zealand J Med. 4:1974;247-252.
71. Miller B., Sarantis M., Traynelis S.F., Attwell D. Potentiation of NMDA receptor currents by arachidonic acid. Nature. 355:1992;722-725.
72. 2. Crit Rev Immunol. 17:1997;225-283.
73. Nilsson A., Horrobin D.F., Rosengren A., Waller L., Adlerberth A., Wilhelmsen L. Essential fatty acids and abnormal involuntary movements in the general male population a study of men born in 1933 . Prostaglandins Leukotriene Essent Fatty Acids. 55:1996;83-87.
74. 2 activity in schizophrenics and other psychiatric patients. Biol Psych. 34:1993;641-649.
75. Obi F.O., Nwanze E.A.C. Fatty acid profiles in mental disease. Part 1. Linolenate variations in schizophrenia. J Neurol Sci. 43:1979;447-454.
76. Peet M., Laugharne J., Rangarajan N., Horrobin D., Reynolds G. Depleted red cell membrane essential fatty acids in drug treated schizophrenic patients. J Psychiatr Res. 29:1995;227-232.
77. Peet M., Laugharne J.D.E., Horrobin D.F., Reynolds G.P. Arachidonic acid a common link in the biology of schizophrenia? Arch Gen Psychiatry. 51:1994;665-666.
78. Peet M., Laugharne J.D.E., Mellor J., Ramchand C.N. Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation. Prostaglandins Leukotriene Essent Fatty Acids. 55:1996;71-75.
79. Peet M, Mellor J (1998): Double-blind placebo controlled trial of n-3 polyunsaturated fatty acids as an adjunct to neuroleptics. Presented at the 9th Schizophrenia Winter Workshop, Davos, Switzerland.
80. 31P nuclear magnetic resonance spectroscopy neurodevelopment and schizophrenia . Schizophr Bull. 19:1993;35-53.
81. Pettegrew J.W., Keshavan M.S., Panchalingam K., Strychor S., Kaplan D.B., Tretta M.G., et al. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex using in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch Gen Psychiatry. 48:1991;563-568.
82. Philbrick D.J., Mahadevappa V.G., Ackman R.G., Holub B.J. Ingestion of fish oil or a derived n-3 fatty acid concentrate containing eicosapentaenoic acid (EPA) affects fatty acid compositions of individual phospholipids of rat brain, sciatic nerve and retina. J Nutr. 117:1987;1663-1670.
83. Prisco D., Filippini M., Francalanci I., Paniccia R., Gensini G.F., Abbate K., et al. Effect of n-3 polyunsaturated fatty acid intake on phospholipid fatty acid composition in plasma and erythrocytes. Am J Clin Nutr. 63:1996;925-932.
84. Puri B.K., Richardson A.J. Sustained remission of positive and negative symptoms of schizophrenia after treatment with eicosapentaenoic acid (letter). Arch Gen Psychiatry. 55:1998;188-189.
85. Reisbick S, Neuringer M (1997): Omega-3 fatty acid deficiency and behavior: a critical review and directions for future research. In: Yehuda S, Mostofsky D, Editors.Handbook of Essential Fatty Acid Biology; Biochemistry, Physiology, and Behavioral Neurobiology. New Jersey: Humana Press, Inc. pp 397-426.
86. Reisbick S., Neuringer M., Hassmain R., Conner W. Polydipsia in rhesus monkeys deficient in omega-3 fatty acids. Physiol Behav. 47:1990;315-323.
87. Ross B.M., Hudson C., Erlich J., Warsh J.J., Kish S.J. Increased phospholipid breakdown in schizophrenia. Arch Gen Psychiatry. 54:1997;487-494.
88. Rotrosen J., Wolkin A. Phospholipid and prostaglandin hypotheses of schizophrenia. Meltzer H.Y., Psychopharmacology The Third Year of Progress . 1987;759-762 Raven Press, New York.
89. Rudin D.O. The major psychoses and neuroses as omega-3 essential fatty acid deficiency syndrome substrate pellagra . Biol Psychiatry. 16:1981;837-850.
90. Rybakowski J., Weterle R. Niacin test in schizophrenia and affective illness. Biol Psychiatry. 29:1991;834-836.
91. Salem N. Jr. Omega-3 fatty acids Molecular and biochemical aspects . Spiller G.A., Scala J., New Protective Roles for Selected Nutrients. 1989;109-228 Alan R Liss Inc, New York.
92. Salem N. Jr. Alcohol, fatty acids and diet. Alcohol Health Res World. 13:1989;211-218.
93. Salem N Jr, Kim HY, Yergey JA (1986): Docosahexaenoic acid: membrane function and metabolism. In: Simopoulos A, Kaifer R, Martin R, editors.Health Effects of Polyunsaturated Fatty Acids in Seafoods. Orlando, FL: Academic Press, pp 263-317.
94. Salem N. Jr, Niebylski C. The nervous system has an absolute molecular species requirement for proper function. Mol Membr Biol. 12:1995;131-134.
95. Salem N. Jr, Ward G. Are omega-3 fatty acids essential nutrients for mammals? Simopoulos A., World Review of Nutrition and Dietetics. 1993;128-147 Karger, Basel. Volume 72.
96. Sawazaki S., Salem N. Jr, Kim H.Y. Lipoxygenation of docosahexaenoic acid by the rat pineal body. J Neurochem. 62:1994;2437-2447.
97. Shah S, Vankar GK, Telang SD, Ramchand CN, Peet M (1998): Eicosapentaenoic Acid (EPA) As An Adjunct In The Treatment Of Schizophrenia. Presented at the 9th Schizophrenia Winter Workshop, Davos.
98. Shioiri T., Kato T., Inubushi T., Murashita J., Takahashi S. Correlations of phosphomonoesters measured by phosphorus-31 magnetic resonance spectroscopy in the frontal lobes and negative symptoms in schizophrenia. Psychiatry Res Neuroimaging. 55:1994;223-235.
99. Stanley J.A., Williamson P.C., Drost D.J., Carr T.J., Rylett R.J., Malla A., et al. An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy. Arch Gen Psychiatry. 52:1995;399-406.
100. Stanley J.A., Williamson P.C., Drost D.J., Carr T.J., Rylett R.J., Morrison-Stewart S., et al. Membrane phospholipid metabolism and schizophrenia an in vivo 31P-MR spectroscopy study . Schizophr Res. 13:1994;209-215.
101. Vaddadi K. Dyskinesias and their treatment with essential fatty acids a review . Prostaglandins Leukotrienes Essent Fatty Acids. 55:1996;89-94.
102. Vaddadi K.S. Penicillin and essential fatty acid supplementation in schizophrenia. Prostaglandins Med. 2:1979;77-80.
103. Vaddadi K.S., Courtney P., Gilleard C.J., Manku M.S., Horrobin D.F. A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatry Res. 27:1989;313-323.
104. 1 precursor in chronic neuroleptic resistant schizophrenic patients. Psychopharmacology. 88:1986;362-367.
105. Vaddadi K.S., Gilleard C.J., Soosai E., Polonowita A.K., Gibson R.A., Burrows G. Schizophrenia, tardive dyskinesia and essential fatty acids. Schizophr Res. 20:1996;287-294.
106. Vidgren H.M., Agren J.J., Schwab U., Rissanen T., Hanninen O., Uusitupa M.I. Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men. Lipids. 32:1997;697-705.
107. Vinogradov S., Gottesman I.I., Moises H.W., Nicol S. Negative association between schizophrenia and rheumatoid arthritis. Schizophr Bull. 17:1991;669-678.
108. Wainwright P.E. Do essential fatty acids play a role in behavioral development? Neurosci Biobehav Rev. 16:1992;193-205.
109. Wainwright PE (1997): Essential fatty acids and behavior: Is there a role for the eicosanoids? In: Yehuda S, Mostofsky D, Editors.Handbook of Essential Fatty Acid Biology; Biochemistry, Physiology, and Behavioral Neurobiology. New Jersey: Humana Press, Inc. pp 299-341.
110. Ward P., Sutherland J., Glen E., Glen A.I., Horrobin D.F. Niacin skin flush in schizophrenia a preliminary report . Schizophr Res. 29:1998;269-274.
111. Williamson P.C., Drost D., Stanley J., Carr T., Morrison S., Merskey H. Localized phosphorus 31 magnetic resonance spectroscopy in chronic schizophrenic patients and normal controls. Arch Gen Psychiatry. 48:1991;578.
112. Wilson D.W.S., Douglass A.B. Niacin skin flush is not diagnostic of schizophrenia. Biol Psychiatry. 21:1986;971-974.
113. Witt M.-R., Nielsen M. Characterization of the influence of unsaturated free fatty acids on brain GABA/benzodiazepine receptor binding in vitro. J Neurochem. 62:1994;1432-1439.
114. Wolkin A., Jordan B., Peselow E., Rubinstein M., Rotrosen J. Essential fatty acid supplementation in tardive dyskinesia. Am J Psychiatry. 143:1986;912-914.
115. Yao J.K., van Kammen D.P. Red blood cell membrane dynamics in schizophrenia. I. Membrane fluidity. Schizophr Res. 11:1994;209-216.
116. Yao J.K., van Kammen D.P., Gurklis J. Red blood cell dynamics in schizophrenia III. Correlation of fatty acid abnormalities with clinical measures. Schizophr Res. 13:1994;227-232.
117. Yao J.K., van Kammen D.P., Gurklis J.A. Abnormal incorporation of arachidonic acid into platelets of drug-free patients with schizophrenia. Psychiatry Res. 60:1996;11-21.
118. Yao J.K., van Kammen D.P., Welker J.A. Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophr Res. 13:1994;217-226.
119. Yehuda S., Rabinovitz S., Mostofsky D. Effects of essential fatty acid preparation (SR-3) on brain lipids, biochemistry, and behavioral and cognitive functions. Yehuda S., Mostofsky D., Handbook of Essential Fatty Acid Biology; Biochemistry, Physiology, and Behavioral Neurobiology. 1997;427-452 Humana Press, Inc, New Jersey.